| Identification | Back Directory | [Name]
LeterMovir | [CAS]
917389-32-3 | [Synonyms]
AIC246
CS-2799
MK-8828
LeterMovir
LeterMovir-005
Letermovir (AIC246)
AIC246;AIC 246;AIC-246
(4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid
4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)- | [EINECS(EC#)]
200-001-8 | [Molecular Formula]
C29H28F4N4O4 | [MDL Number]
MFCD22572725 | [MOL File]
917389-32-3.mol | [Molecular Weight]
572.55 |
| Chemical Properties | Back Directory | [Boiling point ]
706.5±70.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
≥57.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
solid | [pka]
4.00±0.10(Predicted) | [color ]
Off-white to yellow | [InChIKey]
FWYSMLBETOMXAG-QHCPKHFHSA-N | [SMILES]
N1C2=C(C=CC=C2F)[C@H](CC(O)=O)N(C2=CC(C(F)(F)F)=CC=C2OC)C=1N1CCN(C2=CC=CC(OC)=C2)CC1 |
| Hazard Information | Back Directory | [Uses]
Letermovir acts as an orally or i.v administered cytomegalovirus terminus complex inhibitor, antiviral agent, used in the treatment of CMV infection which is prevalent in those with immunocompromised systems. |
|
|